Appclon Registers U.S. Patent for Dual Antibody 'AM201', Secures Rights for Autoimmune Disease Treatment

Dual Antibody Targeting Both IL-6 and TNF-α
Includes Technology to Improve Manufacturing Quality Issues

Appclon announced on May 19 that it has completed registration of a U.S. patent related to the core technology of 'AM201', a candidate for an autoimmune disease treatment based on its dual antibody platform 'AffiMab'.

Appclon company logo image. Appclon

The registered patent covers a polypeptide with enhanced protein purity and antigen affinity, as well as antibody–antigen binding fragment complexes utilizing this polypeptide and their manufacturing methods.

AM201 is a dual antibody candidate designed to simultaneously inhibit IL-6 and TNF-α, which are considered key inflammatory mediators in autoimmune diseases such as rheumatoid arthritis. This represents a strategy to differentiate from existing single-target therapies.

The patent also includes a protein engineering technology to reduce glycosylation-related quality variations that can occur during antibody production. The company explained that this enables improvements in antibody homogeneity and binding properties.

An Appclon representative stated, "This patent registration will serve as a foundation for future global commercialization and expansion of technology partnerships."

This content was produced with the assistance of AI translation services.